NCT03306251

Brief Summary

The purpose of this study is to provide a surveillance system to monitor changes in the rate of mother to child HIV transmission and preventive practices in France and especially to identify the occurrence of toxicity in children exposed perinatally to antiretroviral drugs.

Trial Health

47
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
5,200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2005

Longer than P75 for all trials

Geographic Reach
3 countries

51 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2005

Completed
11.3 years until next milestone

First Submitted

Initial submission to the registry

September 20, 2016

Completed
1.1 years until next milestone

First Posted

Study publicly available on registry

October 11, 2017

Completed
5.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2023

Completed
Last Updated

April 30, 2021

Status Verified

April 1, 2021

Enrollment Period

17.8 years

First QC Date

September 20, 2016

Last Update Submit

April 29, 2021

Conditions

Keywords

HIVPregnancyPrevention of mother-to-child transmission

Outcome Measures

Primary Outcomes (1)

  • Efficacy of PMTCT strategies by measuring rate of mother to child transmission of HIV

    Number of infected children (HIV RNA \>50c/mL or Positive serology) reported on the total number of children

    At birth up to 24 months

Secondary Outcomes (4)

  • Immuno-virological response during pregnancy

    At inclusion up to childbirth

  • Tolerance and toxicity of different kind of MTCT prophylaxis during pregnancy

    At inclusion up to childbirth

  • Impact of different kind of MTCT prophylaxis on childbirth

    At delivery

  • Impact of different kind of MTCT prophylaxis during pregnancy on uninfected children

    At childbirth, 1 month, 3 months, 6 months, 12 months and 18-24 months

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Inclusion as soon as possible during pregnancy of HIV-women in obstetrical sites (15 sites in Paris area, 35 in mainland France and 4 in the DOM)

You may qualify if:

  • pregnant women \>= 18 years
  • infected with HIV1 and/or HIV2

You may not qualify if:

  • guardianship or judicial or administrative detention

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (52)

CHU Hôpital Nord

Amiens, France

RECRUITING

Centre Hospitalier Universitaire

Angers, France

RECRUITING

Centre Hosipitalier

Annecy, France

RECRUITING

Centre Hospitalier Robert Ballanger

Aulnay, France

RECRUITING

Centre Hospitalier Général de Bastia

Bastia, France

RECRUITING

Centre Hospitalier de la Côte Basque

Bayonne, France

RECRUITING

CHRU Saint Jacques

Besançon, France

RECRUITING

Centre hospitalier de Béziers

Béziers, France

RECRUITING

Groupe Hospitalier Pellegrin

Bordeaux, France

RECRUITING

Centre Hospitalier Régional Universitaire de Brest

Brest, France

RECRUITING

CHRU Clemenceau

Caen, France

RECRUITING

Centre Hospitalier William Morey

Chalon-sur-Saône, France

RECRUITING

Centre Hospitalier Général

Creil, France

RECRUITING

CHRU de Dijon

Dijon, France

RECRUITING

Centre Hospitalier Général

Évreux, France

RECRUITING

Centre Hospitalier Général

Fontainebleau, France

RECRUITING

Centre Hospitalier Les Oudayries

La Roche-sur-Yon, France

RECRUITING

Centre Hospitalier de Lagny

Lagny-sur-Marne, France

RECRUITING

Hôpital André Mignot, Versailles

Le Chesnay, France

RECRUITING

Centre Hospitalier Universitaire

Limoges, France

RECRUITING

Centre Hospitalier Général

Longjumeau, France

RECRUITING

Centre Hospitalier Bretagne Sud

Lorient, France

RECRUITING

Centre Hospitalier François Quesnay

Mantes-la-Jolie, France

RECRUITING

Centre Hospitalier de Meaux

Maux, France

RECRUITING

Centre Hospitalier Marc Jacquet

Melun, France

RECRUITING

Centre Hospitalier Intercommunal

Montfermeil, France

RECRUITING

CHU Nancy

Nancy, France

RECRUITING

CHU Caremeau

Nîmes, France

RECRUITING

Centre Hospitalier Régional

Orléans, France

RECRUITING

Centre Hospitalier Général

Orsay, France

RECRUITING

Bon secours-Saint Joseph

Paris, France

RECRUITING

CHG Maréchal Joffre

Perpignan, France

RECRUITING

Centre Hospitalier Intercommunal

Poissy, France

RECRUITING

Centre Hospitalier René Dubos

Pontoise, France

RECRUITING

Centre Hospitalier Léon Binet

Provins, France

RECRUITING

Hôpital Laennec

Quimper, France

RECRUITING

CHR American Memorial Hospital

Reims, France

RECRUITING

CHU Pontchaillou

Rennes, France

RECRUITING

Hôpital Charles Nicolle

Rouen, France

RECRUITING

Centre Hopsitalier Yves Le Foll

Saint-Brieuc, France

RECRUITING

Hôpital Bellevue

Saint-Etienne, France

RECRUITING

Centre hospitalier

Saint-Julien, France

RECRUITING

Hôpital de Saint-Martin

Saint-Martin, France

RECRUITING

Centre Hospitalier de Saint Nazaire-Cité Sanitaire

Saint-Nazaire, France

RECRUITING

Hôpital Font Pré

Toulon, France

RECRUITING

CHRU de Tours

Tours, France

RECRUITING

Centre Hospitalier Bretagne Atlantique

Vannes, France

RECRUITING

Centre Hospitalier

Vernon, France

RECRUITING

Centre Hospitalier Intercommunal

Villeneuve-Saint-Georges, France

RECRUITING

CHG de Cayenne

Cayenne, French Guiana

RECRUITING

CHU Pointe à Pitre, Les Abymes

Pointe-à-Pitre, Guadeloupe

RECRUITING

Hôpital Victor Fouche

Fort-de-France, Martinique

RECRUITING

Related Publications (15)

  • Mandelbrot L, Tubiana R, Le Chenadec J, Dollfus C, Faye A, Pannier E, Matheron S, Khuong MA, Garrait V, Reliquet V, Devidas A, Berrebi A, Allisy C, Elleau C, Arvieux C, Rouzioux C, Warszawski J, Blanche S; ANRS-EPF Study Group. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis. 2015 Dec 1;61(11):1715-25. doi: 10.1093/cid/civ578. Epub 2015 Jul 21.

  • Taron-Brocard C, Le Chenadec J, Faye A, Dollfus C, Goetghebuer T, Gajdos V, Labaune JM, Perilhou A, Mandelbrot L, Blanche S, Warszawski J; France REcherche Nord&Sud Sida-HIV Hepatites - Enquete Perinatale Francaise - CO1/CO11 Study Group. Increased risk of serious bacterial infections due to maternal immunosuppression in HIV-exposed uninfected infants in a European country. Clin Infect Dis. 2014 Nov 1;59(9):1332-45. doi: 10.1093/cid/ciu586. Epub 2014 Jul 22.

  • Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A, Dollfus C, Tubiana R, Bonnet D, Lelong N, Khoshnood B, Warszawski J. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014 Apr 29;11(4):e1001635. doi: 10.1371/journal.pmed.1001635. eCollection 2014 Apr.

  • Briand N, Jasseron C, Sibiude J, Azria E, Pollet J, Hammou Y, Warszawski J, Mandelbrot L. Cesarean section for HIV-infected women in the combination antiretroviral therapies era, 2000-2010. Am J Obstet Gynecol. 2013 Oct;209(4):335.e1-335.e12. doi: 10.1016/j.ajog.2013.06.021. Epub 2013 Jun 18.

  • Briand N, Warszawski J, Mandelbrot L, Dollfus C, Pannier E, Cravello L, Nguyen R, Matheron I, Winer N, Tubiana R, Rouzioux C, Faye A, Blanche S; ANRS-EPF CO1-CO11 Study Group. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era? Clin Infect Dis. 2013 Sep;57(6):903-14. doi: 10.1093/cid/cit374. Epub 2013 May 31.

  • Rachas A, Warszawski J, Le Chenadec J, Legeai C, Teglas JP, Goujard C, Rouzioux C, Mandelbrot L, Tubiana R, Meyer L. Does pregnancy affect the early response to cART? AIDS. 2013 Jan 28;27(3):357-67. doi: 10.1097/QAD.0b013e32835ac8bc.

  • Jasseron C, Mandelbrot L, Dollfus C, Trocme N, Tubiana R, Teglas JP, Faye A, Rouzioux C, Blanche S, Warszawski J. Non-disclosure of a pregnant woman's HIV status to her partner is associated with non-optimal prevention of mother-to-child transmission. AIDS Behav. 2013 Feb;17(2):488-97. doi: 10.1007/s10461-011-0084-y.

  • Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, Czernichow P, Foissac F, Laborde K, Treluyer JM, Firtion G, Layouni I, Munzer M, Bavoux F, Polak M, Blanche S; ANRS French Perinatal Cohort Study Group. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA. 2011 Jul 6;306(1):70-8. doi: 10.1001/jama.2011.915.

  • Sibiude J, Warszawski J, Tubiana R, Dollfus C, Faye A, Rouzioux C, Teglas JP, Ekoukou D, Blanche S, Mandelbrot L. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis. 2012 May;54(9):1348-60. doi: 10.1093/cid/cis198. Epub 2012 Mar 28.

  • Tubiana R, Le Chenadec J, Rouzioux C, Mandelbrot L, Hamrene K, Dollfus C, Faye A, Delaugerre C, Blanche S, Warszawski J. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis. 2010 Feb 15;50(4):585-96. doi: 10.1086/650005.

  • Briand N, Mandelbrot L, Le Chenadec J, Tubiana R, Teglas JP, Faye A, Dollfus C, Rouzioux C, Blanche S, Warszawski J; ANRS French Perinatal Cohort. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS. 2009 Jun 19;23(10):1235-43. doi: 10.1097/QAD.0b013e32832be0df.

  • Mandelbrot L, Jasseron C, Ekoukou D, Batallan A, Bongain A, Pannier E, Blanche S, Tubiana R, Rouzioux C, Warszawski J; ANRS French Perinatal Cohort (EPF). Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales French Perinatal Cohort. Am J Obstet Gynecol. 2009 Feb;200(2):160.e1-9. doi: 10.1016/j.ajog.2008.08.049. Epub 2008 Nov 4.

  • Jasseron C, Mandelbrot L, Tubiana R, Teglas JP, Faye A, Dollfus C, Le Chenadec J, Rouzioux C, Blanche S, Warszawski J; ANRS French Perinatal Cohort. Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immigrants and for French women? AIDS. 2008 Jul 31;22(12):1503-11. doi: 10.1097/QAD.0b013e3283065b8c.

  • Benhammou V, Warszawski J, Bellec S, Doz F, Andre N, Lacour B, Levine M, Bavoux F, Tubiana R, Mandelbrot L, Clavel J, Blanche S; ANRS-Enquete Perinatale Francaise. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS. 2008 Oct 18;22(16):2165-77. doi: 10.1097/QAD.0b013e328311d18b.

  • Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C, Faye A, Burgard M, Rouzioux C, Mandelbrot L; ANRS French Perinatal Cohort. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS. 2008 Jan 11;22(2):289-99. doi: 10.1097/QAD.0b013e3282f3d63c.

Study Officials

  • Josiane WARSZAWSKI

    CESP INSERM U1018

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Josiane WARSZAWSKI

CONTACT

Maud BROSSARD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 20, 2016

First Posted

October 11, 2017

Study Start

June 1, 2005

Primary Completion

March 1, 2023

Study Completion

March 1, 2023

Last Updated

April 30, 2021

Record last verified: 2021-04

Locations